We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A collaboration between Swiss antibody therapeutics firm Humab BioMed and the University of California, Berkeley has given rise to an antibody-based assay which identify Zika infection, even differentiating it from other flaviviruses such as dengue.